Education
About Us
Working with TipRanks
Follow Us
Legend Biotech Corporation (LEGN)
NASDAQ:LEGN
Total Valuation
Legend Biotech has a market cap or net worth of $6.44B. The enterprise value is ―.
Market Cap$6.44B
Enterprise Value―
Share Statistics
Legend Biotech has 183,649,150 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding183,649,150
Owned by Insiders―
Owned by Institutions18.71%
Financial Efficiency
Legend Biotech’s return on equity (ROE) is -0.17 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-0.17
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee241.25K
Profits Per Employee-60.82K
Employee Count2,600
Asset Turnover0.38
Inventory Turnover9.81
Valuation Ratios
The current PE Ratio of Legend Biotech is -16.81. Legend Biotech’s PEG ratio is -0.24.
PE Ratio-16.81
PS Ratio0.00
PB Ratio3.08
Price to Fair Value2.86
Price to FCF-18.50
Price to Operating Cash Flow-22.36
PEG Ratio-0.24
Income Statement
In the last 12 months, Legend Biotech had revenue of 627.24M and earned -177.03M in profits. Earnings per share was -0.97.
Revenue627.24M
Gross Profit392.66M
Operating Income0.00
Pretax Income-158.13M
Net Income-177.03M
EBITDA-113.16M
Earnings Per Share (EPS)-0.97
Cash Flow
In the last 12 months, operating cash flow was -143.37M and capital expenditures -30.65M, giving a free cash flow of -174.02M billion.
Operating Cash Flow-143.37M
Free Cash Flow-174.02M
Free Cash Flow per Share-0.95
Dividends & Yields
Legend Biotech pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change-23.14%
50-Day Moving Average31.70
200-Day Moving Average38.98
Relative Strength Index (RSI)66.42
Average Volume (3m)1.84M
Important Dates
Legend Biotech upcoming earnings date is Aug 29, 2025, TBA Not Confirmed.
Last Earnings DateMay 13, 2025
Next Earnings DateAug 29, 2025
Ex-Dividend Date―
Financial Position
Legend Biotech as a current ratio of 4.62, with Debt / Equity ratio of 33.69%
Current Ratio4.62
Quick Ratio4.54
Debt to Market Cap0.10
Net Debt to EBITDA-0.56
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Legend Biotech has paid 18.89M in taxes.
Income Tax18.89M
Effective Tax Rate-0.12
Enterprise Valuation
Legend Biotech EV to EBITDA ratio is -53.14, with an EV/FCF ratio of -38.03.
EV to Sales9.59
EV to EBITDA-53.14
EV to Free Cash Flow-38.03
EV to Operating Cash Flow-41.75
Balance Sheet
Legend Biotech has $1.12B in cash and marketable securities with $350.60M in debt, giving a net cash position of -$772.08M billion.
Cash & Marketable Securities$1.12B
Total Debt$350.60M
Net Cash-$772.08M
Net Cash Per Share-$4.20
Tangible Book Value Per Share$4.74
Margins
Gross margin is 61.69%, with operating margin of 0.00%, and net profit margin of -28.22%.
Gross Margin61.69%
Operating Margin0.00%
Pretax Margin-25.21%
Net Profit Margin-28.22%
EBITDA Margin-18.04%
EBIT Margin-21.76%
Analyst Forecast
The average price target for Legend Biotech is $80.14, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$80.14
Price Target Upside128.97% Upside
Analyst ConsensusStrong Buy
Analyst Count17
Revenue Growth Forecast112.46%
EPS Growth Forecast54.33%